Key result
Zotarolimus-eluting Endeavor stents outperform bare metal stents with personalized DAPT in uncertain DES candidates.
Why the study?
Optimal duration of dual antiplatelet therapy after coronary revascularization, especially after DES implantation, remains debated, particularly in patients at high bleeding or thrombotic risk who were excluded from prior randomized trials.
Does the use of drug-eluting stents with personalized DAPT duration improve outcomes compared to bare metal stents in patients at high bleeding or thrombotic risk?
Does the use of drug-eluting stents with personalized DAPT duration improve outcomes compared to bare metal stents in patients at high bleeding or thrombotic risk?
This review highlights that drug-eluting stents with personalized DAPT duration may be superior to bare metal stents even in patients at high bleeding or thrombotic risk.
No takes yet. Share an insight, caveat, or question.
Supports zotarolimus-eluting stents with personalized DAPT over bare metal in uncertain candidates; extends prior stent trials to tailored therapy settings.
Ariotti et al. (2015) conducted a review in High bleeding or thrombotic risk requiring coronary revascularization. Drug-eluting stents (Zotarolimus-eluting Endeavor Sprint Stent) vs. Bare metal stents was evaluated. The Zotarolimus-eluting Endeavor Sprint stent demonstrated superiority over bare metal stents in uncertain DES candidates who followed a personalized dual antiplatelet therapy duration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: